





Cite this: *Biomater. Sci.*, 2023, **11**, 3450

Solute transport in the brain tissue: what are the key biophysical parameters tying *in vivo* and *in vitro* studies together?

Daniel Alcaide,^a Jean Cacheux,^{a,b} Aurélien Bancaud,^c  ^{a,b,c} Rieko Muramatsu^d and Yukiko T. Matsunaga  ^{*a,b}

The mechanisms of solute transport in brain tissues are still under debate. The medical relevance of this topic has put the blood–brain barrier and the mechanisms of solute transport through the brain parenchyma in the spotlight, notably in the context of brain clearance. In the last decade, the classical view of pure diffusive flow across the brain parenchyma was tested against the recent proposal of an active, convective fluid flow model known as the glymphatic model. Experimental studies of brain transport on living humans and animals have temporal and spatial limitations to validate any of these models. Therefore, detailed microscopic observations, mostly *ex vivo* tissue and simplified *in vitro* brain models with the support from computational models, are necessary to understand transport mechanisms in brain tissues. However, standardization is lacking between these experimental approaches, which tends to limit the generality of conclusions. In this review, we provide an overview of the output and limitations of modern brain solute transport studies to search for key parameters comparable across experimental setups. We emphasize that *in vitro* models relying on physiological material and reproducing the biophysical setting of the brain, as well as computational/mathematical models constitute powerful solutions to understand the solute transport phenomena inside of the brain tissue. Finally, we suggest the blood–brain barrier permeability and the apparent diffusion coefficient through the brain parenchyma to be robust biophysical parameters for the extraction of cross-model conclusion.

Received 7th January 2023,
Accepted 25th March 2023

DOI: 10.1039/d3bm00027c
rsc.li/biomaterials-science

Introduction

The brain vasculature is composed of tightly joint endothelial cells with specific transport systems that differ from the rest of the organism's vasculature. This interface is known as the blood–brain barrier (BBB), and it is responsible for brain homeostasis and protection against damaging circulating agents.^{1–3} The integrity of the BBB is critical for correct brain functioning.⁴ Several diseases are associated with BBB dysfunction, such as stroke, epilepsy, multiple sclerosis, Alzheimer's disease, and mental disorders.⁵ Given this multi-disease and pluri-field relevance, medical studies regarding transport mechanisms through the BBB and preservation of its adequate functioning have gained attention in the past decades.

However, solute transport in the parenchyma after passing the BBB has not yet been fully elucidated. Because the brain was typically thought to be lacking lymphatic clearance, solute transport through the extracellular space (ECS) was classically attributed to diffusive movements.^{6,7} In the last decade, the evidence for a fluid clearance pathway in the nervous system (CNS), the so-called glymphatic system has been proposed. This system considers active water and ion transport from the periarterial spaces through the interstitial space to the perivascular space. This occurs thanks to polarized water channels, specifically aquaporin-4 (AQP-4), and ionic channels on the membrane of a type of glial cells, known as astrocytes, in a convective, directional manner with arterial pulsation cyclic movements as flow motor force.^{8,9} Studies have confirmed the presence of a meningeal lymphatic vessel network along the outer dura mater of the brain that leads to the lymphatic nodes in the skull base,^{10,11} showing that diffusion may not be all about solute movement through the brain's ECS and leaving space for models that also consider convective flow.

Dysfunction of the glymphatic system can reduce waste removal from the brain tissue, leading to neuroinflammation and CNS disorders such as Alzheimer's disease, associated with the accumulation of amyloid- β and tau. Fluid clearance in

^aInstitute of Industrial Science, The University of Tokyo, Tokyo 153-8505, Japan.
E-mail: mat@iis.u-tokyo.ac.jp

^bLIMMS, CNRS-IIS UMI 2820, The University of Tokyo, Tokyo 153-8505, Japan

^cCNRS, LAAS, 7 Avenue Du Colonel Roche, F-31400 Toulouse, France

^dDepartment of Molecular Pharmacology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-higashi, Kodaira, Tokyo 187-8502, Japan



the glymphatic system is mostly active during sleep. However, this system degrades with age, suggesting a causal link between sleep disturbances and the progression of neurodegenerative dementia symptoms. Thus, fluid transport through glymphatic system has been considered as a potential therapeutic target for CNS diseases.^{12,13} Drugs can also affect the glymphatic function of the brain, mainly through the modulation of CSF-ISF exchange and AQP-4 channels. Special attention has been paid to anesthetic drugs, which induce unconsciousness and increase glymphatic function.^{13,14} However, the mechanisms of action of these drugs seem to impact glymphatic function modulation, suggesting that they affect brain transport more globally than only through anesthesia.¹⁴

In the glymphatic context, astrocytes are thought to be relevant to fluid transport through the brain parenchyma. However, astrocytes also have various functions in the brain, depending on their surrounding neural tissues, ranging from molecular homeostasis maintenance by transporting major ions, protons, and neurotransmitter precursors, to defining the cytoarchitecture of the gray matter, working as structural guides with connections to the vasculature.¹⁵ Astrocytes located near the brain microvasculature revolve around it with their endfeet, where the expression of AQP-4 appears particularly relevant.¹⁶ Those endfeet constitute an intricate layer, normally referred to as the astrocytic endfeet network, which separates the perivascular spaces filled with cerebrospinal fluid (CSF)^{8,9,17} from the brain parenchyma full of interstitial fluid (ISF). CSF and ISF have a similar composition but serve different purposes. Waste from neural activities are secreted directly into the ISF, from where they are removed and leave the central nervous system (CNS) through the CSF.¹⁸ CSF also serves as the buoyancy cushion for the brain and compensates for the blood volume changes inside the skull. Astrocytes are thought to work as a regulator of the CSF-ISF exchange through the periarterial spaces into the brain ECS and out of the brain through the perivenous spaces, thanks to AQP-4 water channels^{19,20} (Fig. 1).

Nonetheless, conflicting experimental results regarding the glymphatic model have been found. Huge differences in microvasculature coverage by the endfeet network have been observed in *ex vivo* samples using different cell fixation methods before electron microscopy imaging,²¹ which raises doubts about the sieving function of astrocytes. Some experiments even suggest that basal membranes contribute or in some cases substitute the sieving function of the endfeet network.¹⁷ At the capillary scale, the basal membrane is fused between the endfeet network and the endothelial barrier,^{22,23} which makes differentiating the filtering contribution of each structure difficult. Albargothy *et al.* have also indicated the existence of pathways for the CSF influx through the basal membrane structures in the brain arterioles of mice.²⁴

Other controversies come from the use of animal models, which have considerably progressed to allow the application of invasive observation techniques. Disagreement arises from key differences between animal and human brains. The astrocyte-




Fig. 1 Glymphatic system schematic. Arrows represent direction of the flow inside of the vasculature, perivascular spaces, and brain parenchyma. AQP-4 channels present mostly in astrocyte endfeet assist the flow of CSF from the periarterial space into the brain parenchyma and clears the ISF containing waste, such as amyloid- β and tau, through the perivenous space.

to-neuron ratio is higher in humans than in rodents, and human astrocytes are approximately 2.6 times larger in diameter. In the rodent brain, pericytes around the microvasculature appear to guide AQP-4 polarization, but this conclusion is questionable in human.^{25,26} These disagreements may be avoided using *in vitro* models (normally referred to as microfluidic chips or brain-on-a-chip) employing human cell lines. Thanks to three-dimensional (3D) cocultures of relevant cell lines (astrocytes, endothelial cells, *etc.*), researchers recapitulate biological phenomena in a controlled environment and perform real-time and high-resolution observations. Transport across the BBB²⁷ is one of the most common mechanism studied on *in vitro* platforms, whereas solute transport through the extracellular matrices (ECMs) appears to be quite out of the conversation probably due to the difficulty in recreating accurate brain ECM *in vitro*.

Many great reviews summarizing current brain solute transport models and concepts have been published in the last decade.^{18,28} However, not so many pursue the parametrical analysis of such models considering the standardization of measurements. By identifying parameters measurable in various experimental setups, cross-study conclusion extraction may become easier. Thus, this review summarizes recent results of experiments on solute transport through the brain parenchyma. We look at solute transport studies through the whole brain parenchyma and transport studies at the cellular scale, where *in vitro* models also provide interesting input. Then, we briefly overview the attempts of computational modeling to tie all previous studies together. Finally, we discuss relevant biophysical parameters that could be used for validation purposes across all those approaches (Fig. 2).






Fig. 2 Schematic of the general concept of this review paper. Blue text: general advantage of the study/model. Red text: major disadvantage of the study/model. General brain solute transport models should be validated by both large scale and microscopic scale observations, with the help of both specific *in vitro* and *in silico* approximation to analyse and understand and validate the brain solute transport models.

Brain-scale transport observations

To observe the fluid movement inside the brain, studies are mainly conducted *in vivo*. Since transport through the brain parenchyma was initially thought to be purely diffusive, experiments over two decades quantitatively measured the apparent diffusion coefficient (ADC) of tracers in the human brain to distinguish the gray matter, white matter, and CSF. ADC is commonly understood as the diffusion coefficient obtainable from measurements such as magnetic resonance images, and it was then used to indicate possible methodological uncertainties that may influence the pure diffusion coefficient measured value. Previously published values of ADC of water in living humans are $(2.9\text{--}3) \times 10^{-3} \text{ mm}^2 \text{ s}^{-1}$ for CSF, $(0.75\text{--}1) \times 10^{-3} \text{ mm}^2 \text{ s}^{-1}$ for the gray matter, and $(0.2\text{--}1) \times 10^{-3} \text{ mm}^2 \text{ s}^{-1}$ depending on which part of the white matter is measured.^{29,30} At baseline, the self-diffusion coefficient of water at 35 °C is approximately $2.9 \times 10^{-3} \text{ mm}^2 \text{ s}^{-1}$,^{31,32} which is basically the same value as the water ADC in the CSF. In a more recent study, Valnes *et al.* used diffusion tensor images to determine the ADCs of water in both gray and white matters, obtaining $1.1 \pm 0.3 \times 10^{-3} \text{ mm}^2 \text{ s}^{-1}$ and $0.8 \pm 0.2 \times 10^{-3} \text{ mm}^2 \text{ s}^{-1}$, respectively, in the healthy human brain, which is still in the range of previously mentioned records.³³

In a more recent noninvasive study conducted in living humans, Wu *et al.* observed complete contrast agent clearance from the CSF in a span of 18 h maximum on 217 patients, based on sequential magnetic resonance images after intravenous administration of gadobutrol (Fig. 3A).³⁴ The clearance from the periarterial spaces to the perivenous spaces and lastly




Fig. 3 Whole brain flow visualization. (A) Contrast enhanced gadolinium (Gd) T2 FLAIR images. Perivenous enhancement and Gd leakage are visible (arrows). Follow-up images 18 h after initial images present no Gd signals.³⁴ © 2020 American Neurological Association. (B) Computational calculation of ICP variation (colormap) and CSF velocity u (arrows) due to cardiac pulsations.⁵⁰ The pulsation is divided in high net blood inflow (phase I), end of the net blood inflow (phase II), inflow and outflow equilibrium (phase III) and high blood net outflow (phase IV).⁵¹

to the meningeal lymphatics was observed, which follows the path predicted by the glymphatic theory. Other experiments in the same line revealed that drainage of intrathecally injected tracers to the lymphatic nodes in the skull base takes up to 24 h.³⁵ These experiments are suitable for the evaluation of the overall movement of the CSF and ISF inside the brain; however, observations both in real time and at high resolution are lacking, inhibiting us from observing brain waste removal mechanisms in action.

Higher temporal and spatial resolutions can be achieved while remaining *in vivo* in animal models using more invasive observational procedures. A cranial opening is typically carved in the skull of the test subjects, allowing for detailed observations of the outer brain layers.^{36,37} So far, however, these studies have suffered from the critical issue associated to the change in the intracranial pressure (ICP) to the atmospheric pressure.³⁸ Studies have proved that even small variations in the ICP can significantly change the results of ISF transport experiments.^{39,40} Notably, increased ICP after intrathecal injection in the closed skull of mice was one of the controversial points by which early glymphatic model experiments were criticized, although later low-flow injections in large brain cav-



ities do not increase ICP significantly.⁴⁰ Other factors, which contribute to change the ICP, including the stage of development and position of the subjects during the experiment, tend to affect the consistency of results across experimental setups.^{41,42} Thus, recently, other techniques that enable the monitoring of the ICP have been tested. Demeulenaere *et al.* mapped the whole mouse brain vasculature by non-invasive ultrafast ultrasound localization. This technique allowed the imaging of 0.3 mm × 0.3 mm² volumes 750 times per s.⁴³ These are incredibly promising results for large-volume, highly resolved, and non-invasive vasculature imaging that could be applied to humans; although these types of studies, which require acquisitions of several tens of seconds and a processing time of several hours, have not been published yet.

Experiments with living subjects also allow researchers to monitor effects of the whole organism in brain solute transport, such as the sleeping state, vascular pulsations, or disease. Studies on the natural necessity for sleeping and its implications on brain clearance show that during sleeping hours, brain permeability is enhanced and the interstitial space volume is increased by up to 60%.⁴⁴ Demiral *et al.* studied variations in slow and fast ADC in the sleeping human brain, showing an increase in the overall CSF volume, but only localized changes in these coefficients in the sleeping brain. Astrocytes may help regulate sleep homeostasis⁴⁵ through changes in their cell volume in favor of greater interstitial space volume in the sleeping brain, facilitating CSF-ISF flux throughout the brain.^{46,47} Regarding vascular pulsations,⁴⁸ a study suggested the coexistence of different pulsations moving CSF along perivascular spaces.⁴⁹ Data from such studies has recently motivated computational models that also show the relationship between CSF displacement and ICP variations during cardiac pulsation cycles (Fig. 3B).^{50,51}

Related studies have shown general behaviors of brain fluid dynamics, mostly ignoring how microscopic elements such as the different cell barriers and astrocyte AQP-4 channels may influence CFS-ISF movements through the brain parenchyma. One way to identify the relevance on the fluid transport of those microscopic elements in the brain is to have them be altered artificially by drugs,¹⁴ due to disease or any other special conditions in the subjects, and then compare them with control subjects. This notably occurs in Alzheimer's disease, where AQP-4 depolarization and glymphatic impairment take place.⁵² Disease-like effects are also seen in genetically mutated mice with non-expression of AQP-4.^{53–56} To our knowledge, only a few noninvasive studies on AQP-4-deficient mice have been published, and some of them have reported a significant decrease in the water exchange rate between the brain vasculature and parenchyma through non-invasive MRI.⁵⁴ Still, most of these studies conduct brain dissection for microscopic observations.

Cellular-scale observations

For microscopic observations, biopsied brain tissue is usually collected from animals, *postmortem* humans, or sometimes

from living humans as part of another surgical process. The extracted tissue is then subjected to fixation that preserves it *ex vivo*, or when taken from a living subject, it can be kept alive inside a controlled *in vitro* microenvironment that provides it sufficient oxygen and nutrients for its survival. The latter technique is still not widely used; however, the coupling of *in vitro* devices with brain samples can produce very interesting platforms.^{57–60} Fixed brain tissue is much easier to handle, although the combination of terminal ischemia and the fixation process induce adverse effects on the cellular structure of the tissue, up to reducing the ECM space in half.³⁶

D'Arceuil *et al.* compared the ADC of primate (macaque) brains *in vivo*, *postmortem ex vivo*, and fixed samples. *In vivo* ADC values are in the same range as those in humans, as stated in the previous section. However, ADC values decrease in the white matter to 48% ± 20% and 20% ± 16% of the *in vivo* value in *postmortem ex vivo* and fixed brains, respectively. A similar degree of variation was observed for the gray matter.⁶¹ In another study, Thelwall *et al.* demonstrated that fixation processes, specifically aldehyde-based fixation, irreversibly reduce cell membrane permeation.⁶² A more recent study showed relevant morphological differences in mouse brain slices between chemical fixation and cryofixation. Specifically, astrocyte endfeet vasculature coverage appears to rise from 62.9% in cryofixation to 94.4% in chemical fixation (Fig. 4A), where the ECS has nearly completely collapsed (Fig. 4B).²¹ Cryofixation is thought to preserve better the *in vivo*-like tissue structure than chemical fixation, although the latter is the most commonly used. Surprisingly, D'Arceuil *et al.* also showed that diffusion anisotropy, *i.e.*, the diffusion coefficient variation as a function of the direction inside the brain tissue, present in *in vivo* brains is well preserved in *ex vivo* fixed samples.⁶¹

Despite these alterations, we cannot disregard the useful information about the structure of the BBB and the parenchymal astrocyte endfeet network provided by microscopic observations in biopsied tissue. Nuriya and Yasui *et al.* used mice brain slices to show that astrocytic endfeet revolving around the brain vasculature constitute a slow diffusive barrier that may control solute concentrations around the BBB, whereas the rest of the astrocytic processes present higher diffusion rates. This local decrease in diffusion rates may allow astrocytes to regulate each region of the BBB.^{19,63} Similarly, Ezan *et al.* showed that the depletion of some gap junction proteins present in astrocytic endfeet, which occurs under several neuropathological conditions,⁶⁴ weakens the BBB, making it leaky under stress.⁶⁵ Also, brain disease mice models have proven to be clinically relevant tools, even showing perturbed patterns of AQP-4 expression throughout the brain tissue similar to *post-mortem* humans in Alzheimer's disease studies.⁶⁶

Deep analysis of brain tissues reveals some differences in AQP-4 distribution between human and rodent brains. Higher contents of AQP-4 in human astrocyte's parenchymal membranes have been reported, whereas endfeet surrounding the vasculature appear to have similar AQP-4 densities in both cases.²⁶ When working with AQP-4 null mice, Saadoun *et al.*






Fig. 4 Chemically fixed and cryofixed brain tissue presents morphological differences. (A) Average vasculature coverage in cryo and chemically fixed mouse brain tissue. (B) Electro micrograph images of transversal sections of cryo and chemically fixed cerebral tissue (astrocytic endfeet colored). Chemically fixed samples present almost complete vasculature covering by the astrocytic endfeet while some uncovered areas can be seen in cryo fixed samples.²¹

did not detect abnormalities in brain morphology nor BBB integrity.⁶⁷ Even so, under edema conditions, AQP-4 null mice experience greater brain water accumulation than wild-type mice,⁶⁸ suggesting that AQP-4 not only participates in the inflow of water into the brain (even during brain edema formation),⁶⁹ but also in the outflow of water from the brain. However, these experiments are extremely difficult to replicate in human brain tissues, leaving the door open for extrapolation and interpretation of these results in humans. An attempt to closing this gap is through engineered culture systems using human cell lines to approximate the brain anatomy *in vitro* or directly employing biopsied living human tissues, even though the latter is harder to come by.

In vitro models

Brain *in vitro* models attempted to recapitulate the basic biological and physical elements of the brain, also known as brain-on-a-chip (BoC). These models offer researchers controlled; high-throughput systems where precise measurements can be made. Standard 2D culture systems, which involve endothelial cells interacting with other cell types through porous membranes, are simple to reproduce and cost-effective but lack physiological relevance.⁷⁰ Instead, 3D engineered cultures are built onto microfluidic devices with cell cultures of endothelial cells, typically cocultured with pericytes and/or astrocytes to recreate the structure of the 3D BBB and the brain tissue as close as possible to the pathophysiological conditions.^{71,72} The relevance of these systems would rely on the correct representation of key characteristics such as engineered ECM composition, endothelial BBB tightness, coculture cellular interactions, selective permeability and diffusion rates and pressure and stress responses, among others.⁷³

Unfortunately, the direct use of human brain cells or brain tissue is not always possible because the cellular materials are limited and endothelial brain cells tend to lose their pheno-

type during the cell handling process.⁷⁴ Recent studies have addressed this limitation using human-induced pluripotent stem cells that differentiate into brain endothelial human cells.⁷⁵ This technique have also been implemented in pericyte cells.⁷⁶ It is also not uncommon to find *in vitro* assays using animal cell lines instead of human cell lines.^{73,77,78} In addition, as the cell lines of choice for BoC models might vary, BoC device design and measurement readout are also often different among models. This variety of BoC platforms complicates cross-model comparisons, which is the reason for the requests for standardization of measurements on microfluidic platforms in the last decade.^{27,79,80} van der Helm *et al.* suggested the use of the measured permeability coefficient or apparent permeability coefficient of multiple analytes, which can be calculated in each device, to compare model results with *in vivo* measurements. If the geometry of the device allows for it, they also suggest placing electrodes for measuring transendothelial electrical resistance (TEER) for barrier tightness assessment.²⁷

The geometrical disposition of the BoC model directly affects BBB permeability measurements and requires calibration to confirm physical relevance of the model.²⁷ Non-transwell microfluidic BoC devices (Fig. 5A) enable shear stress and hydrodynamic pressure effects over the BBB to be controlled by endothelial cells directly in contact with the ECM that contains supporting cellular coculture. Cylindrical geometries also influence the EC phenotype, morphology, and polarization of key proteins.⁸¹ However, unlike in 2D and 2.5D, TEER measurements in cylindrical 3D models are more difficult and normally substituted by tracer permeability studies modeled after radial diffusion of molecules from a cylindrical source.⁸² In addition, most 3D cylindrical models have much larger diameters (100–800 μm) than brain capillaries. Thus far, the only way to achieve diameters as low as 30 μm is through vasculogenesis; however, it is still in development, and the measurement of BBB permeability is very complicated.⁸⁰






Fig. 5 Common geometric and cellular compositions of BoC systems. (A) Schematic of typical setups of 2D, 2.5D, 3D, and vasculogenesis brain-on-a-chip models. 2D model: EC culture is separated from the supporting cell cocultures by a porous membrane. Shear stress effects are hard to maintain, but transport observations and TEER measurements are easy to perform. 2.5D model: non-cylindrical 3D EC culture in contact with an external ECM containing supporting cell coculture by one of its walls (2D cell interaction). Shear effects are maintained while still easing transport observations and TEER measurements. 3D cylindrical model: cylindrical vessel suspended in ECM containing coculture. Great shear flow and geometrical effects in ECs, but TEER measurements are more complex. 3D vasculogenesis model: ECs grow smaller capillaries between two larger ones. This method requires specific ECM compositions, but local measurements are hard to perform.⁸⁰ (B) Confocal views of 3D BBB coculture models. Schematic, longitudinal and cross-section views are presented. ECs are colored in pink, whereas PC and astrocytes appear in green. Scale bar, 200 μm.⁸⁶

An *in vivo* like BBB structure is achieved in BoC models when endothelial cells create a continuous layer and present junctions rich in tight junction proteins (occludin, claudin-5 and ZO-1).^{83,84} The cellular response to shear stress and pressure in a 3D matrix motivates the formation of these tight cellular junctions and lowers cell barrier permeability.^{27,85} Herland *et al.* also showed that the coculture of endothelial cylindrical BBB with pericytes or astrocytes (Fig. 5B)⁸⁶ decreases the diffusive permeability of endothelial barriers, which relates to the diffusive flux through the barrier, against small molecules (3 kDa). The diffusive permeability values measured in monoculture conditions were $4 \times 10^{-6} \text{ cm s}^{-1}$, $3 \times 10^{-6} \text{ cm s}^{-1}$ in pericyte coculture and $2 \times 10^{-6} \text{ cm s}^{-1}$ in astrocyte coculture. This may result from an increase in tight junction proteins induced by the presence of astrocytes and/or pericytes. Some experiments use astrocyte-conditioned medium instead of astrocytes because of its lower cost and simple storage.⁸⁷ However, results obtained in BoCs with astrocyte-conditioned medium are inconsistent, showing both an increase and a decrease in BBB permeability.^{84,88} Therefore, the use of astrocytes is preferred. Other factors that may influence the BBB permeability are disease-related biochemical compounds, such as pro-inflammatory cytokines, *e.g.*, tumor necrosis factor alpha (TNF- α), which decreased severely the integrity of the cultured BBB.^{85,86}

Similar to their *in vivo* counterparts, cases where *in vitro* astrocyte AQP-4 polarization on the endfeet facing the cultured endothelial barrier have been reported. This phenotype appears to be specific to 3D cultures.⁸⁹ Indeed, 2D-cultured astrocytes become active, a process known as reactive gliosis, and they present less AQP-4 polarization than when they are cultured in a 3D hydrogel.⁹⁰ Even more, the composition of the hydrogel matrix plays a major role on *in vitro* astrocyte development. Hydrogels such as collagen, commonly used *in vitro* culture are far from the real brain ECM, where collagen cannot be found.⁹¹ Astrocyte activation and morphology was different in collagen hydrogels than hydrogels mixing other components also present in the brain ECM, such as hyaluronic acid and/or proteoglycan compounds by adding Matrigel.⁹² Astrocytes branched much more in hydrogels containing those three materials and remained inactive, much more like they are found *in vivo*. These early approaches towards a more physiologically relevant *in vitro* ECM are motivating the design of glymphatic *in vitro* platforms focusing on the transport across astrocyte cultured ECM. Using a 4 : 1 : 1 mixture of collagen type 1, Matrigel and hyaluronic acid, a very recent glymphatics-on-a-chip was proposed.⁹³ The chip consisted in two parallel endothelial vessels passing through one common chamber containing the astrocyte seeded hydrogel. Transport of an amyloid- β solution from one vessel to the other was observed but no control over the hydrostatic pressure gradient between the vessels was incorporated in the design.

For future transport studies, as argued by Wan *et al.*, the use of relevant *ex vivo* samples into microfluidic devices and the fine control of the hydrostatic pressure gradient across the ECM in glymphatics-on-a-chip would be necessary for accurate



transport studies through the parenchyma simulation.⁹⁴ Since this pressure gradient is likely to determine the mechanism of transport driven by diffusion or advection, recreating the same range of pressure gradients present inside the brain *in vivo* for accurate *in vitro* representation is strongly advised. Development in this direction is being made: for instance, Coloma *et al.* studied reverse transport in the perivascular spaces on *in vitro* platforms with quantified fluid transport velocity and different boundary conditions.⁹⁵ Still, there is a severe lack of *in vitro* platforms where pressure gradient and its consequences onto the brain tissue deformation and permeability are taken into consideration. The employment of engineered hydrogels, whose composition, mechanical properties, and influence in cell cultures can be very well characterized and tuned,⁹⁶ may ease the future design of these pressure-controlled glymphatics-on-a-chip devices. For now, one way to study such effects are computational models.

In silico models

To broaden our insight into brain solute transport, well known aspects of brain physiology can be coupled with mathematical calculations of the parenchymal flow in computational/mathematical models, commonly known as *in silico* models. *In silico* models are constructed to test the robustness of hypotheses extracted from experimental observations, and they may also serve to find a hierarchy between parameters that control the solute transport in the brain.⁹⁷ Normally, *in silico* models can be highly detailed but focused in specific areas of the parenchymal flow phenomena or broader in their modeling area but sacrificing fine details in favor of computational viability.⁹⁸

Highly localized parenchymal transport *in silico* models are capable to use finite-element or even analytical methods in most cases. Under these settings, models isolate specific sections of the brain for study. Using a finite-element modeling of poroelastic brain tissue around a penetrating arteriole,

Table 1 Summary of the parameters used by four selected *in silico* models and the conclusions extracted from them. Two models do not consider astrocytes and/or AQP-4 as contributors to flow through the brain parenchyma, but all four conclude that diffusion should be the main transport mechanism through the brain parenchyma

Model type	Ref.	Parameters and considerations	Conclusions
Hydraulic resistance model	102	<ul style="list-style-type: none"> ■ Distance between vessels = 300 μm ■ Astrocyte domain diameter = 50 μm ■ Flow pathways: <ol style="list-style-type: none"> (1) Endfeet AQP-4 only for water (2) Inter-endfeet for solutes up to 20 nm (3) Basement membrane contributions ■ Gap junction resistance to water between astrocytes (2.5–4.5 nm) ■ Pressure gradient between consecutive PVS = 226 Pa 	<ul style="list-style-type: none"> ■ Whole astrocytes facilitate water exchange through AQP-4 in all the CNS tissue. ■ Diffusion dominates in the parenchyma. Advection and diffusion both occur in the PVS. ■ AQP-4 depletion hinders the flow rate up to 46%.
	103	<ul style="list-style-type: none"> ■ Distance between vessels = 200 μm ■ Vessel radius = 10 μm ■ Pulse frequency = 5 Hz ■ Hydraulic conductivity = $5.63 \times 10^{-12} \text{ m}^2 \text{ Pa}^{-1} \text{ s}^{-1}$ ■ Vessel porosity = 0.2 ■ Pore size = 60 nm ■ Parenchyma as solid porous media 	<ul style="list-style-type: none"> ■ Pulsation induces 0 net flow in PVS; dispersion might be a better explanation of fluid movement. ■ Peak fluid velocity is small ($<6 \text{ nm s}^{-1}$) regardless of parameter change, indicative of mainly diffusion driven flow.
Tissue digital reconstruction	104	<ul style="list-style-type: none"> ■ 3D model from the electron microscopy of rat neuropil ■ Pressure gradient = 1 mmHg mm^{-1} ■ Diffusion coefficients: <ol style="list-style-type: none"> (1) Potassium ion = $77 \times 10^{-7} \text{ cm}^2 \text{ s}^{-1}$ (2) 3 kDa dextran = $5.3 \times 10^{-7} \text{ cm}^2 \text{ s}^{-1}$ (3) 70 kDa dextran = $0.84 \times 10^{-7} \text{ cm}^2 \text{ s}^{-1}$ ■ Permeability of the smallest element = $10.7 \text{ nm} \times 19 \text{ nm}^2$ 	<ul style="list-style-type: none"> ■ Extracellular flow velocity of $8.95\text{--}16 \text{ nm s}^{-1}$. ■ Solute movement is very constrained. Diffusion should be the main mechanism. ■ Advection can take place only in the PVS.
	105	<ul style="list-style-type: none"> ■ 2D model from the primate cerebral cortex ■ Effective hydraulic conductance of ECM = $0.9 \times 10^{-9} \text{ cm}^4 \text{ per (dyne per s)}$ ■ Diffusion coefficients of solute A = $10^{-9} \text{ m}^2 \text{ s}^{-1}$ and solute B = $0.2\text{--}5 \times 10^{-10} \text{ m}^2 \text{ s}^{-1}$ ■ AC permeability = $0\text{--}0.4 \text{ cm s}^{-1}$ ■ Pressure periarterial space = $0\text{--}10 \text{ mmHg}$ ■ Pressure amplitude of pulsation = $0\text{--}100 \text{ mmHg}$ 	<ul style="list-style-type: none"> ■ AQP-4 affects only osmotically driven water transport. ■ Diffusion is sufficient to explain results. ■ Advection in the parenchyma is unlikely.



Kedarasetti *et al.* found that arterial pulsations could drive convective flow through the ECM.⁹⁹ Transport through the perivascular spaces is also a common topic of this kind of models, either on idealized or image-based geometries.^{100,101} In their perivascular flow model, Vinje *et al.* found that geometry differences between periarterial and perivenous spaces favor flow velocity in the first ones, which is in agreement with some previous experimental data.

On the other hand, more complete parenchymal transport *in silico* models brain fluid transport commonly consider the following basic elements: an influx source into the ECM (normally the periarterial space), different transport channels through the EC (AQP-4 channels, paracellular pathways, *etc.*), and an outflow source from the ECM (normally the perivenous space). Flow calculation may be performed by translating the fluid movement into an electric circuit based on hydraulic resistance paths^{102,103} or simulating the biological tissue based on electron microscopy images of brain tissue and then implementing Navier-Stokes^{104,105} and/or Darcy model^{106,107} calculations on them.

In these hydrodynamic or poromechanic models, parameters such as the scale, ECM geometry, flow-driving forces, and astrocyte contributions, among others, may be implemented differently,⁹⁷ which leads to slight differences in their conclusions. Table 1 shows the parameters and general conclusions of four example parenchymal flow models. Regardless of small deviations, these four models agree that diffusion through the ECM is the principal mechanism of transport, as the majority of *in silico* brain clearance models do.^{102–105} However, only two of them pointed out that astrocytic AQP-4 channels may be a major facilitator of ISF flow.^{102,104} Meanwhile, more recent general models describe fluid movement in the brain as the composition of diffusion with net zero mean flow induced by the cyclic arterial pulsation, *i.e.*, dispersion,¹⁰⁷ which also substitutes the need for advective flow to explain brain clearance.¹⁰⁸

Some issues arise with the use of *in silico* models when trying to approach specific experimental conditions, for example, AQP-4 depletion in the brain or disease-like conditions. Models tend to represent such states as a variation of some of their computational variables, such as trans-membrane water resistance or a decrease in the interfeet gaps of astrocytes.^{109,110} Meanwhile, *in vivo* experiments have shown that, in the case of AQP-4 depletion for example, the ECM volume fraction and diffusivity throughout the brain is also altered.¹¹¹ This issue is less severe in localized *in silico* models, which can portray a more accurate representation of those phenomena thanks to being focused on a relatively small area of the brain physiology. Therefore, it should be of great interest to build computationally viable models that can incorporate the findings of both *in vivo* studies and other specific *in silico* models into a generalized parenchymal transport model.

Conclusions and future perspectives

In this review, we have summarized the scale and limitations of current solute brain transport studies, considering their

reach and relevant parameters that can be obtained from them. Undoubtedly, *in vivo* studies are the most relevant of the brain clearance phenomena. However, studies in living humans fail to provide macroscopic readouts that definitely clarify the physical mechanisms of transport and clearance, although projects toward this goal are ongoing.¹¹² There is a lack of sensitivity for probing interstitial flow. Therefore, other studies should support and seek an explanation of such behaviors at a smaller scale with high-resolution observations. To confirm the results of different models efficiently, several steps toward the standardization of measurements should be taken.

On this review, we saw through the different sections how important correct brain tissue representation is when evaluating experimental results. Employment of *ex vivo* samples runs into the disadvantage of substantially modifying the brain tissue properties, due to terminal ischemia and fixation. *In vitro* models suffer of inaccurate ECM representation and poor control of the periodic gradients applied to the brain tissue by cardiac pulsations. *In silico* models lose detail when englobing different areas of the brain. The common issue among these is being distant from brain tissue physiology or the inaccurate representation of it in the case of *in silico* models. We think that relevant progress on the matter would be possible by including soft material physics into the equation, both on *in vitro* and *in silico* models.

When it comes to transport across the brain tissue, we propose diffusion coefficients as good standardizing candidates. Most *in silico* brain transport models include the diffusion coefficients of the solutes that they simulate as general calculation parameters. Similarly, ADCs or diffusive permeability englobe microscopic effects such as AC AQP-4 contributions to diffusive flow macroscopically. They can be calculated from MR images of living brains³³ and in *ex vivo* tissue, even though the values obtained *ex vivo* are typically lower than that obtained from *in vivo* measurements.^{61,62} It would be interesting if the lowering ratio between *in vivo* and *ex vivo* ADCs remains in the same range in every direction of the brain tissue due to the conservation of diffusion anisotropy.⁶¹ This would allow the *ex vivo* ADC values to be taken more quantitatively. The measurement of effective diffusion coefficients *in vitro* (especially from 3D microfluidic cylindrical models) can also be a relatively simple task. Unfortunately, as discussed previously transport through the ECM is still not the main topic of brain *in vitro* models. Improving the *in vitro* ECM physiological relevance and allowing pressure control would be major milestones in the development of relevant lymphatics-on-a-chip models.

Because the flux by diffusion is conservative, brain-scale measurements can be connected to local insights on the BBB. In this context, the porosity of the barrier, or equivalently the diffusive permeability, are relevant to standardized validation. *In vitro* models allow BBB permeability measurement relatively easily through TEER measurements and tracer transport studies; however, most studies do not provide such measurements in their publications. On the other hand, BBB permeability measurement *in vivo* is yet a challenging task.



Without observing the flow through the BBB at the microscopic scale in humans, only general fluid movement inside the brain can be used to infer BBB permeability. This could be solved with measurements on biopsied *in vivo* tissue in platforms such as BoC devices, and computational models can implement BBB permeability as one of their variables as the validation test for the permeability values obtained from other experiments.

In summary we discuss the necessity for cross-model validation parameters for brain clearance and solute transport studies. This review compiled the outputs from different techniques used to examine brain solute transport mechanisms. This is a complex process, involving the transport across the BBB, diffusion, and periodic pressure actuation by the cardiac pulses. A lack of attention to the coupling of the periodic pressure actuation and the soft, elastic brain tissue was observed. Interest in this matter is starting to rise, which can be seen in the depiction of dispersion fluid movements or poroelastic properties of the brain tissue implemented in some mathematical models. However, *in vitro* platforms are still behind and need to incorporate pressure controlling elements for a precise glymphatics-on-a-chip model development. We believe that this type of device would become a powerful tool in brain disease drug assessment and overall brain research. Finally, regarding the questions of data integration, we suggest that it is possible by defining simple and multiscale readouts such as ADCs when regarding parenchymal transport and cell barrier permeability in the case transport across the BBB, both representative of the overall brain tissue. However, we think that this analysis will be even more powerful after the effect of periodic pressure and ECM permeability/mechanical properties in the context of dispersion of fluid in the brain tissue are clarified first.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

D. A. acknowledges the doctoral fellowship from WINGS-QSTEP. J. C. acknowledges the JSPS for postdoctoral fellowship. The authors thank the LIMMS (CNRS-Institute of Industrial Science, University of Tokyo) for the financial support. This work was partially supported by the AMED-CREST (22gm1510009) and the JSPS Core-to-Core Program (grant no. JPJSCCA20190006).

Notes and references

- W. G. Mayhan, *Microcirculation*, 2001, **8**, 89–104.
- N. J. Abbott, *J. Anat.*, 2002, **200**, 523–534.
- M. M. A. Almutairi, C. Gong, Y. G. Xu, Y. Chang and H. Shi, *Cell. Mol. Life Sci.*, 2016, **73**, 57–77.
- R. Daneman and A. Prat, *Cold Spring Harbor Perspect. Biol.*, 2015, **7**, a020412.
- K. Schoknecht and H. Shalev, *Epilepsia*, 2012, **53**, 7–13.
- E. Syková and C. Nicholson, *Physiol. Rev.*, 2008, **88**, 1277–1340.
- A. S. Verkman, *Phys. Biol.*, 2013, **10**, 045003.
- J. J. Iliff, M. Wang, Y. Liao, B. A. Plogg, W. Peng, G. A. Gundersen, H. Benveniste, G. E. Vates, R. Deane, S. A. Goldman, E. A. Nagelhus and M. Nedergaard, *Sci. Transl. Med.*, 2012, **4**, 147ra111.
- N. A. Jessen, A. S. F. Munk, I. Lundgaard and M. Nedergaard, *Neurochem. Res.*, 2015, **40**, 2583–2599.
- A. Louveau, I. Smirnov, T. J. Keyes, J. D. Eccles, S. J. Rouhani, J. D. Peske, N. C. Derecki, D. Castle, J. W. Mandell, K. S. Lee, T. H. Harris and J. Kipnis, *Nature*, 2015, **523**, 337–341.
- A. Aspelund, S. Antila, S. T. Proulx, T. V. Karlsen, S. Karaman, M. Detmar, H. Wiig and K. Alitalo, *J. Exp. Med.*, 2015, **212**, 991–999.
- M. Nedergaard and S. A. Goldman, *Science*, 2020, **370**, 50–56.
- T. J. Lohela, T. O. Lilius and M. Nedergaard, *Nat. Rev. Drug Discovery*, 2022, **21**, 763–779.
- H. Benveniste, H. Lee, F. Ding, Q. Sun, E. Al-Bizri, R. Makaryus, S. Probst, M. Nedergaard, E. A. Stein and H. Lu, *Anesthesiology*, 2017, **127**, 976–988.
- A. Verkhratsky and M. Nedergaard, *Physiol. Rev.*, 2018, **98**, 239–389.
- T. M. Mathiisen, K. P. Lehre, N. C. Danbolt and O. P. Ottersen, *Glia*, 2010, **58**, 1094–1103.
- M.-J. Hannocks, M. E. Pizzo, J. Huppert, T. Deshpande, N. J. Abbott, R. G. Thorne and L. Sorokin, *J. Cereb. Blood Flow Metab.*, 2018, **38**, 669–686.
- S. B. Hladky and M. A. Barrand, *Fluids Barriers CNS*, 2014, **11**, 26.
- M. Nuriya, T. Shinotsuka and M. Yasui, *Cereb. Cortex*, 2013, **23**, 2118–2126.
- S. Michinaga and Y. Koyama, *Int. J. Mol. Sci.*, 2019, **20**, 571.
- N. Korogod, C. C. Petersen and G. W. Knott, *eLife*, 2015, **4**, e05793.
- A. W. J. Morris, R. O. Carare, S. Schreiber and C. A. Hawkes, *Front. Aging Neurosci.*, 2014, **6**, 251.
- R. Hallmann, N. Horn, M. Selg, O. Wendler, F. Pausch and L. M. Sorokin, *Physiol. Rev.*, 2005, **85**, 979–1000.
- N. J. Albarogthy, D. A. Johnston, M. MacGregor-Sharp, R. O. Weller, A. Verma, C. A. Hawkes and R. O. Carare, *Acta Neuropathol.*, 2018, **136**, 139–152.
- G. A. Gundersen, G. F. Vindedal, Ø. Skare and E. A. Nagelhus, *Brain Struct. Funct.*, 2014, **219**, 2181–2186.
- V. A. Eidsvaag, R. Enger, H.-A. Hansson, P. K. Eide and E. A. Nagelhus, *Glia*, 2017, **65**, 964–973.
- M. W. van der Helm, A. D. van der Meer, J. C. T. Eijkel, A. van den Berg and L. I. Segerink, *Tissue Barriers*, 2016, **4**, e1142493.
- C. F. Ferris, *Front. Neurosci.*, 2022, **16**, 854377.



- 29 D. Le Bihan, R. Turner, P. Douek and N. Patronas, *AJR, Am. J. Roentgenol.*, 1992, **159**, 591–599.
- 30 J. H. Burdette, D. D. Durden, A. D. Elster and Y. F. Yen, *J. Comput. Assist. Tomogr.*, 2001, **25**, 515–519.
- 31 R. Mills, *J. Phys. Chem.*, 1973, **77**, 685–688.
- 32 M. Holz, S. R. Heil and A. Sacco, *Phys. Chem. Chem. Phys.*, 2000, **2**, 4740–4742.
- 33 L. M. Valnes, S. K. Mitusch, G. Ringstad, P. K. Eide, S. W. Funke and K.-A. Mardal, *Sci. Rep.*, 2020, **10**, 9176.
- 34 C.-H. Wu, J.-F. Lirng, Y.-H. Ling, Y.-F. Wang, H.-M. Wu, J.-L. Fuh, P.-C. Lin, S.-J. Wang and S.-P. Chen, *Ann. Neurol.*, 2021, **89**, 111–124.
- 35 P. K. Eide, S. A. S. Vatnehol, K. E. Emblem and G. Ringstad, *Sci. Rep.*, 2018, **8**, 7194.
- 36 R. G. Thorne and C. Nicholson, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 5567–5572.
- 37 H. Hirase, L. Qian, P. Barthó and G. Buzsáki, *PLoS Biol.*, 2004, **2**, e96.
- 38 M. T. Oberdier, J. F. Antaki, A. Kharlamov and S. C. Jones, *Anim. Models Exp. Med.*, 2021, **4**, 391–397.
- 39 H. Mestre, Y. Mori and M. Nedergaard, *Trends Neurosci.*, 2020, **43**, 458–466.
- 40 B. Bedussi, M. Almasian, J. de Vos, E. VanBavel and E. N. Bakker, *J. Cereb. Blood Flow Metab.*, 2018, **38**, 719–726.
- 41 M. Moazen, A. Alazmani, K. Rafferty, Z.-J. Liu, J. Gustafson, M. L. Cunningham, M. J. Fagan and S. W. Herring, *J. Biomech.*, 2016, **49**, 123–126.
- 42 S.-J. Guild, F. D. McBryde and S. C. Malpas, *J. Appl. Physiol.*, 2015, **119**, 576–581.
- 43 O. Demeulenaere, A. Bertolo, S. Pezet, N. Ialy-Radio, B. Osmanski, C. Papadacci, M. Tanter, T. Deffieux and M. Pernot, *EBioMedicine*, 2022, **79**, 103995.
- 44 L. Xie, H. Kang, Q. Xu, M. J. Chen, Y. Liao, M. Thiyagarajan, J. O'Donnell, D. J. Christensen, C. Nicholson, J. J. Iliff, T. Takano, R. Deane and M. Nedergaard, *Science*, 2013, **342**, 373–377.
- 45 P. G. Haydon, *Curr. Opin. Neurobiol.*, 2017, **44**, 28–33.
- 46 A. R. Mendelsohn and J. W. Larrick, *Rejuvenation Res.*, 2013, **16**, 518–523.
- 47 Ş. B. Demiral, D. Tomasi, J. Sarlls, H. Lee, C. E. Wiers, A. Zehra, T. Srivastava, K. Ke, E. Shokri-Kojori, C. R. Freeman, E. Lindgren, V. Ramirez, G. Miller, P. Bandettini, S. Horovitz, G.-J. Wang, H. Benveniste and N. D. Volkow, *NeuroImage*, 2019, **185**, 263–273.
- 48 J. J. Iliff, M. Wang, D. M. Zeppenfeld, A. Venkataraman, B. A. Plog, Y. Liao, R. Deane and M. Nedergaard, *J. Neurosci.*, 2013, **33**, 18190–18199.
- 49 V. Kiviniemi, X. Wang, V. Korhonen, T. Keinänen, T. Tuovinen, J. Autio, P. LeVan, S. Keilholz, Y.-F. Zang, J. Hennig and M. Nedergaard, *J. Cereb. Blood Flow Metab.*, 2016, **36**, 1033–1045.
- 50 M. Causemann, V. Vinje and M. E. Rognes, *Fluids Barriers CNS*, 2022, **19**, 1–17.
- 51 O. Balédent, in *Adult Hydrocephalus*, ed. D. Rigamonti, Cambridge University Press, Cambridge, 2014, pp. 121–138.
- 52 B. C. Reeves, J. K. Karimy, A. J. Kundishora, H. Mestre, H. M. Cerci, C. Matouk, S. L. Alper, I. Lundgaard, M. Nedergaard and K. T. Kahle, *Trends Mol. Med.*, 2020, **26**, 285–295.
- 53 F. Zhao, J. Deng, X. Xu, F. Cao, K. Lu, D. Li, X. Cheng, X. Wang and Y. Zhao, *J. Neuroinflammation*, 2018, **15**, 157.
- 54 Y. Ohene, I. F. Harrison, P. Nahavandi, O. Ismail, E. V. Bird, O. P. Ottersen, E. A. Nagelhus, D. L. Thomas, M. F. Lythgoe and J. A. Wells, *NeuroImage*, 2019, **188**, 515–523.
- 55 G. T. Manley, M. Fujimura, T. Ma, N. Noshita, F. Filiz, A. W. Bollen, P. Chan and A. S. Verkman, *Nat. Med.*, 2000, **6**, 159–163.
- 56 Z. Xu, N. Xiao, Y. Chen, H. Huang, C. Marshall, J. Gao, Z. Cai, T. Wu, G. Hu and M. Xiao, *Mol. Neurodegener.*, 2015, **10**, 58.
- 57 Y. Huang, J. C. Williams and S. M. Johnson, *Lab Chip*, 2012, **12**, 2103–2117.
- 58 C. Rae and V. J. Balcar, in *Brain Energy Metabolism*, ed. J. Hirrlinger and H. S. Waagepetersen, Springer, New York, NY, 2014, pp. 217–241.
- 59 P. Herreros, S. Tapia-González, L. Sánchez-Olivares, M. F. Laguna Heras and M. Holgado, *Int. J. Mol. Sci.*, 2022, **23**, 2549.
- 60 S. Bang, S. Jeong, N. Choi and H. N. Kim, *Biomicrofluidics*, 2019, **13**, 051301.
- 61 H. E. D'Arceuil, S. Westmoreland and A. J. de Crespigny, *NeuroImage*, 2007, **35**, 553–565.
- 62 P. E. Thelwall, T. M. Shepherd, G. J. Stanisz and S. J. Blackband, *Magn. Reson. Med.*, 2006, **56**, 282–289.
- 63 M. Nuriya and M. Yasui, *J. Neurosci.*, 2013, **33**, 3692–3698.
- 64 C. Giaume, A. Koulakoff, L. Roux, D. Holcman and N. Rouach, *Nat. Rev. Neurosci.*, 2010, **11**, 87–99.
- 65 P. Ezan, P. André, S. Cisternino, B. Saubaméa, A.-C. Boulay, S. Doutremer, M.-A. Thomas, N. Quenech'du, C. Giaume and M. Cohen-Salmon, *J. Cereb. Blood Flow Metab.*, 2012, **32**, 1457–1467.
- 66 D. M. Zeppenfeld, M. Simon, J. D. Haswell, D. D'Abreo, C. Murchison, J. F. Quinn, M. R. Grafe, R. L. Woltjer, J. Kaye and J. J. Iliff, *JAMA Neurol.*, 2017, **74**, 91–99.
- 67 S. Saadoun, M. J. Tait, A. Reza, D. C. Davies, B. A. Bell, A. S. Verkman and M. C. Papadopoulos, *Neuroscience*, 2009, **161**, 764–772.
- 68 M. C. Papadopoulos, G. T. Manley, S. Krishna and A. S. Verkman, *FASEB J.*, 2004, **18**, 1291–1293.
- 69 G. T. Manley, M. Fujimura, T. Ma, N. Noshita, F. Filiz, A. W. Bollen, P. Chan and A. S. Verkman, *Nat. Med.*, 2000, **6**, 159–163.
- 70 J. A. Kim, H. N. Kim, S.-K. Im, S. Chung, J. Y. Kang and N. Choi, *Biomicrofluidics*, 2015, **9**, 024115.
- 71 L. A. Low, C. Mummery, B. R. Berridge, C. P. Austin and D. A. Tagle, *Nat. Rev. Drug Discovery*, 2021, **20**, 345–361.
- 72 S. N. Bhatia and D. E. Ingber, *Nat. Biotechnol.*, 2014, **32**, 760–772.
- 73 R. Booth and H. Kim, *Lab Chip*, 2012, **12**, 1784–1792.
- 74 N. J. Abbott, D. E. M. Dolman, S. R. Yusof and A. Reichel, in *Drug Delivery to the Brain: Physiological Concepts*,



- Methodologies and Approaches*, ed. M. Hammarlund-Udenaes, E. C. M. de Lange and R. G. Thorne, Springer, New York, NY, 2014, pp. 163–197.
- 75 T. Qian, S. E. Maguire, S. G. Canfield, X. Bao, W. R. Olson, E. V. Shusta and S. P. Palecek, *Sci. Adv.*, 2017, **3**, e1701679.
- 76 X. Tian, O. Brookes and G. Battaglia, *Sci. Rep.*, 2017, **7**, 39676.
- 77 H. Cho, J. H. Seo, K. H. K. Wong, Y. Terasaki, J. Park, K. Bong, K. Arai, E. H. Lo and D. Irimia, *Sci. Rep.*, 2015, **5**, 15222.
- 78 G. Adriani, D. Ma, A. Pavesi, R. D. Kamm and E. L. K. Goh, *Lab Chip*, 2017, **17**, 448–459.
- 79 A. Wolff, M. Antfolk, B. Brodin and M. Tenje, *J. Pharm. Sci.*, 2015, **104**, 2727–2746.
- 80 M. E. Katt and E. V. Shusta, *Curr. Opin. Chem. Eng.*, 2020, **30**, 42–52.
- 81 D. Baptista, L. Teixeira, C. van Blitterswijk, S. Giselbrecht and R. Truckenmüller, *Trends Biotechnol.*, 2019, **37**, 838–854.
- 82 R. Habibey, J. E. Rojo Arias, J. Striebel and V. Busskamp, *Chem. Rev.*, 2022, **122**, 14842–14880.
- 83 M. McRae, L. M. LaFratta, B. M. Nguyen, J. J. Paris, K. F. Hauser and D. E. Conway, *Tissue Barriers*, 2018, **6**, e1405774.
- 84 A. García-Salvador, A. Domínguez-Monedero, P. Gómez-Fernández, A. García-Bilbao, S. Carregal-Romero, J. Castilla and F. Goñi-de-Cerio, *ATLA, Altern. Lab. Anim.*, 2020, **48**, 184–200.
- 85 L. M. Griep, F. Wolbers, B. de Wagenaar, P. M. ter Braak, B. B. Weksler, I. A. Romero, P. O. Couraud, I. Vermes, A. D. van der Meer and A. van den Berg, *Biomed. Microdevices*, 2013, **15**, 145–150.
- 86 A. Herland, A. D. van der Meer, E. A. FitzGerald, T.-E. Park, J. J. F. Sleeboom and D. E. Ingber, *PLoS One*, 2016, **11**, e0150360.
- 87 E. Vandenhaute, E. Sevin, D. Hallier-Vanuxeem, M.-P. Dehouck and R. Cecchelli, *Drug Discovery Today*, 2012, **17**, 285–290.
- 88 M. Culot, S. Lundquist, D. Vanuxeem, S. Nion, C. Landry, Y. Delplace, M.-P. Dehouck, V. Berezowski, L. Fenart and R. Cecchelli, *Toxicol. in Vitro*, 2008, **22**, 799–811.
- 89 S. I. Ahn, Y. J. Sei, H.-J. Park, J. Kim, Y. Ryu, J. J. Choi, H.-J. Sung, T. J. MacDonald, A. I. Levey and Y. Kim, *Nat. Commun.*, 2020, **11**, 175.
- 90 J.-K. Yoon, J. Kim, Z. Shah, A. Awasthi, A. Mahajan and Y. Kim, *Adv. Healthcare Mater.*, 2021, **10**, 2002285.
- 91 E. Ruoslahti, *Glycobiology*, 1996, **6**, 489–492.
- 92 A. L. Placone, P. M. McGuiggan, D. E. Bergles, H. Guerrero-Cazares, A. Quiñones-Hinojosa and P. C. Searson, *Biomaterials*, 2015, **42**, 134–143.
- 93 P. A. Soden, A. R. Henderson and E. Lee, *Adv. Biol.*, 2022, **6**, 2200027.
- 94 J. Wan, S. Zhou, H. J. Mea, Y. Guo, H. Ku and B. M. Urbina, *Chem. Rev.*, 2022, **122**, 7142–7181.
- 95 M. Coloma, J. D. Schaffer, P. Huang and P. R. Chiarot, *BiOMICROFLUIDICS*, 2019, **13**, 024103.
- 96 U. Blache, E. M. Ford, B. Ha, L. Rijns, O. Chaudhuri, P. Y. W. Dankers, A. M. Kloxin, J. G. Snedeker and E. Gentleman, *Nat. Rev. Methods Primers*, 2022, **2**, 1–22.
- 97 A. D. Martinac and L. E. Bilston, *Biomech. Model. Mechanobiol.*, 2020, **19**, 781–800.
- 98 D. H. Kelley and J. H. Thomas, *Annu. Rev. Fluid Mech.*, 2023, **55**, 237–264.
- 99 R. T. Kedarasetti, P. J. Drew and F. Costanzo, *Fluids Barriers CNS*, 2022, **19**, 34.
- 100 V. Vinje, E. N. T. P. Bakker and M. E. Rognes, *Sci. Rep.*, 2021, **11**, 16085.
- 101 C. Daversin-Catty, I. G. Gjerde and M. E. Rognes, *Front. Phys.*, 2022, **10**, 882260.
- 102 M. Asgari, D. de Zélicourt and V. Kurtcuoglu, *Sci. Rep.*, 2015, **5**, 15024.
- 103 J. Rey and M. Sarntinoranont, *Fluids Barriers CNS*, 2018, **15**, 20.
- 104 B.-J. Jin, A. J. Smith and A. S. Verkman, *J. Gen. Physiol.*, 2016, **148**, 489–501.
- 105 K. E. Holter, B. Kehlet, A. Devor, T. J. Sejnowski, A. M. Dale, S. W. Omholt, O. P. Ottersen, E. A. Nagelhus, K.-A. Mardal and K. H. Pettersen, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**, 9894–9899.
- 106 A. K. Diem, R. O. Carare, R. O. Weller and N. W. Bressloff, *PLoS One*, 2018, **13**, e0205276.
- 107 M. Asgari, D. de Zélicourt and V. Kurtcuoglu, *Sci. Rep.*, 2016, **6**, 38635.
- 108 C. A. Hawkes, N. Jayakody, D. A. Johnston, I. Bechmann and R. O. Carare, *Brain Pathol.*, 2014, **24**, 396–403.
- 109 D. K. Binder, M. C. Papadopoulos, P. M. Haggie and A. S. Verkman, *J. Neurosci.*, 2004, **24**, 8049–8056.
- 110 X. Yao, S. Hrabětová, C. Nicholson and G. T. Manley, *J. Neurosci.*, 2008, **28**, 5460–5464.
- 111 E. A. Nagelhus and O. P. Ottersen, *Physiol. Rev.*, 2013, **93**, 1543–1562.
- 112 S. Y. Huang, T. Witzel, B. Keil, A. Scholz, M. Davids, P. Dietz, E. Rummert, R. Ramb, J. E. Kirsch, A. Yendiki, Q. Fan, Q. Tian, G. Ramos-Llordén, H.-H. Lee, A. Nummenmaa, B. Bilgic, K. Setsompop, F. Wang, A. V. Avram, M. Komlosh, D. Benjamini, K. N. Magdoo, S. Pathak, W. Schneider, D. S. Novikov, E. Fieremans, S. Tounekti, C. Mekkaoui, J. Augustinack, D. Berger, A. Shapson-Coe, J. Lichtman, P. J. Basser, L. L. Wald and B. R. Rosen, *NeuroImage*, 2021, **243**, 118530.

